The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Tocilizumab Fails to Help COVID-19 Patients in Italian Study

June 23, 2020 • By Emilio Parodi & Carl O'Donnell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial.

You Might Also Like
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • China Approves Use of Tocilizumab for Coronavirus Patients
  • Tocilizumab Begins Clinical Trial for COVID-19

Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease caused by the new coronavirus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Tocilizumab did not reduce severe respiratory symptoms, intensive care visits, or death any better than standard treatments, the Italian Medicines Agency (Aifa), Italy’s drugs regulator which authorized the study, said in a statement.

The trial, which enrolled 126 patients, about a third of the intended number, was stopped early after an interim analysis raised doubts about the anti-inflammatory medicine’s effectiveness.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Although not effective in all patients with COVID-19 pneumonia, it is possible that selected subgroups of patients may have a better response,” Aifa says.

Sales of tocilizumab jumped 30% in the first quarter, Roche said in April, on hopes it would help in the fight against the new coronavirus.

Its failure to do so in the Italian study now adds to questions about the role of drugs like tocilizumab, which are designed to inhibit interleukin (IL) 6 proteins associated with dangerous inflammation, in treating COVID-19.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A similar IL-6 inhibitor, Sanofi and Regeneron’s arthritis drug Kevzara (sarilumab), failed in a trial in April to help a group comprised of severely ill and critically ill patients, leading the drugmakers to continue to test high doses of Kevzara only in those considered critically ill with COVID-19.

Detailed data from the Italian tocilizumab study, which involved 24 medical centres, will be sent to a scientific journal.

Meanwhile, Roche has completed enrolment of its own tocilizumab study in patients hospitalized with severe COVID-19 pneumonia. That “will provide robust evidence about the benefit/ risk profile”, a Roche spokesman said, with data expected in the next few months.

Last month, Roche also announced plans to study whether combining tocilizumab with Gilead Sciences Inc’s antiviral treatment remdesivir works better against severe COVID-19 pneumonia than remdesivir alone.

Remdesivir has shortened hospital stays of COVID-19 patients.

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, tocilizumab

You Might Also Like:
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • China Approves Use of Tocilizumab for Coronavirus Patients
  • Tocilizumab Begins Clinical Trial for COVID-19
  • Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)